MTIC is primarily known as an intermediate metabolite of certain alkylating agents used in cancer chemotherapy, such as dacarbazine and temozolomide. Its main application lies in oncology, where it functions as the active compound responsible for transferring methyl groups to DNA. This methylation damages tumor cell DNA, particularly at the O6 position of guanine, leading to cell cycle arrest and apoptosis. Because of this mechanism, MTIC plays a critical role in the treatment of cancers like melanoma and glioblastoma multiforme. Its ability to cross the blood-brain barrier enhances its effectiveness in treating brain tumors. Research continues to explore ways to improve the delivery and efficacy of drugs that generate MTIC while minimizing resistance mechanisms in cancer cells.